Liminatus Pharma, Inc. (LIMN): Nasdaq/NYSE listing notice — Liminatus Pharma receives Nasdaq delinquency notice for late Q2 10-Q filing; has 60 days to submit compliance plan

Liminatus Pharma, Inc.

Nasdaq notified Liminatus on Aug 22, 2025 of non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q for period ended June 30, 2025.
Company has 60 days, until Oct 21, 2025, to submit a plan to regain compliance; Nasdaq may grant extension to Feb 16, 2026 if plan accepted.
Common stock (LIMN) continues to trade on Nasdaq; no immediate delisting effect.
Liminatus is a pre-clinical stage biopharma developing immune-modulating cancer therapies.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

August 22, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”). The deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “LIMN” at this time. Under the Nasdaq rules, the Company has 60 calendar da

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-082579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.